Anti-191P4D12 (clone Ha22-2(2,4)6.1)-VC-MMAE ADC
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- U.S.A
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- adc
- Category
- Pharmaceuticals
Creative Biolabs
U.S.A
- Verified Certificate
-
8
| Product name | Anti-191P4D12 (clone Ha22-2(2,4)6.1)-VC-MMAE ADC | Certification | - |
|---|---|---|---|
| Category | Pharmaceuticals | Ingredients | - |
| Keyword | adc | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | U.S.A | Stock | - |
| Supply type | - | HS code | - |
Product Information
This ADC product is comprised of an anti-191P4D12 monoclonal antibody (clone Ha22-2(2,4)6.1)) conjugated via a VC linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood. Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest. Binds to tubulins, interrupts microtubule dynamics.
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- Mr
- Address
- SUITE 203, 17 Ramsey Road, Shirley, NY 11967, USA
- Product Category
- Other Pharmaceutical Chemicals
- Year Established
- 2005
- Company introduction
-
Creative Biolabs is a leading company of recombinant antibody (rAb) discovery and manufacturing, providing high quality service to customers in academia and industry fields all over the world.Our cutting-edge hybridoma development and phage display platforms allow the production of the most comprehensive list of recombinant antibody products and extensive service portfolio at the most competitive price. Our products range from antibody / peptide libraries, Biosimilar cell lines, Chimeric antigen receptor (CAR) products, antibody-drug conjugates (ADCs) to engineered antibodies such as therapeutic antibodies, nanobodies, bispecific antibodies and intrabodies. We also provide professional custom antibody discovery and engineering services, featuring phage display library construction, antibody humanization, chimerization, engineered antibody production (Fab, scFc, tribody, bispecific antibody, nanobody, minibody, etc.), antibody labeling, hybridoma/stable cell line development, membrane protein production and cGMP-manufacturing which enable larger scale antibody production for development of animal-based assays and clinical trials.
- Main Product
_2.jpg "Recombinant Human Anti_Golimumab Antibody _Kd _ 2_8 nM__1")
_2.jpg "VINIX ORAL DISSOLVING FILM 50mg_100mg_Sildenafil_50mg_100mg__2")
